Skip to content

Financial Information

This section of the Karyopharm Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  Karyopharm Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQKPTI
Beta0.31
Shares Outstanding75.1M
Average Volume (10 days)1.6M
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($2.72)
Sales (TTM)$1.20
Book Value (MRQ)$0.67
Cash Flow (TTM)($2.22)
Cash (MRQ)$3.38

Analyst Views

Current Mean RecommendationStrong Buy
Strong Buy5
 
Buy1
 
Hold1
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Michael G. Kauffman
Director, Chief Executive Officer
(4,000)
Sell
Mar 18, 2021
Sharon Shacham
President & CSO
(4,000)
Sell
Mar 18, 2021
Michael Mason
SVP, CFO & Treasurer
22,013
Acquire
Feb 25, 2021
Michael G. Kauffman
Director, Chief Executive Officer
57,200
Acquire
Feb 25, 2021
Ran Frenkel
EVP, Chief Dev. Officer
22,013
Acquire
Feb 25, 2021

Recent SEC Filings

CT ORDER
Apr 19, 2021
DEFA14A
Apr 7, 2021
Proxy Statement
Apr 7, 2021
Insider Buy/Sell
Mar 23, 2021
Insider Buy/Sell
Mar 23, 2021
I agree to the storing and processing of my personal data by Karyopharm as described in the Privacy Policy and to the Terms of Use . I agree to receive communications from Karyopharm and understand that I can unsubscribe at any time.